Topical lidocaine enhanced by laser pretreatment: A safe and effective method of analgesia for facial rejuvenation

Georgette Oni, Yvonne Rasko, Jeffrey Kenkel

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Background: Injectable forms of anesthesia for nonsurgical facial rejuvenation, although efficacious, are uncomfortable for the patient. Preclinical studies have demonstrated that laser pretreatment at low energies enhances absorption of topical lidocaine. Objectives: The authors assess the safety and efficacy of laser-assisted transdermal delivery of topical anesthetic. Method: Ten patients were split into 2 groups (A and B). All patients received 15 g of BLT (20% benzocaine, 6% lidocaine, and 4% tetracaine triple anesthetic cream) for 20 minutes with no occlusion. Then the cream was removed and the first blood draw taken. Group A patients were pretreated with the full ablative laser and group B patients with a fractional ablative laser to the full face. A further 15 g BLT was applied for another 20 minutes. Group A patients then underwent full ablative laser treatment, and group B received fractionated ablative laser treatment. Blood draws were taken at 60, 90, 120, 180, and 240 minutes after the initial topical anesthetic application, and the serum was analyzed for lidocaine and monoethylglycinexylidide (MEGX) levels. Patients were asked to rate the pain felt at intervals during the procedure. Results: No patient required supplemental nerve blocks. Pain scores were equivalent at the end of the first pass for both groups (P = .436). Group A patients had significantly lower pain scores at the start of the second laser treatment (P = .045), but pain scores became equivalent by the end (P = .323). Combined serum lidocaine and MEGX levels were significantly higher in group A patients up to 90 minutes (peak average of 0.61 μg/mL for group A and 0.533 ìg/mL for group B; P = .0253), which corresponded to greater initial analgesic effect. Conclusions: Data from this study demonstrate that topical anesthetic for facial rejuvenation can be enhanced with laser pretreatment while maintaining safe blood serum levels. Further studies should examine optimal application amount and time to allow safe multipass facial rejuvenation without the need for invasive nerve blocks.

Original languageEnglish (US)
Pages (from-to)854-861
Number of pages8
JournalAesthetic Surgery Journal
Volume33
Issue number6
DOIs
StatePublished - Aug 2013

Fingerprint

Rejuvenation
Lidocaine
Analgesia
Lasers
monoethylglycinexylidide
Local Anesthetics
Pain
Nerve Block
Serum
Benzocaine
Tetracaine
Analgesics
Anesthetics
Therapeutics
Anesthesia

Keywords

  • cosmetic medicine
  • laser-assisted transdermal delivery
  • pain
  • research
  • topical anesthetics

ASJC Scopus subject areas

  • Surgery

Cite this

Topical lidocaine enhanced by laser pretreatment : A safe and effective method of analgesia for facial rejuvenation. / Oni, Georgette; Rasko, Yvonne; Kenkel, Jeffrey.

In: Aesthetic Surgery Journal, Vol. 33, No. 6, 08.2013, p. 854-861.

Research output: Contribution to journalArticle

@article{64ca6b70f25d4aba80286b0fe8f628b2,
title = "Topical lidocaine enhanced by laser pretreatment: A safe and effective method of analgesia for facial rejuvenation",
abstract = "Background: Injectable forms of anesthesia for nonsurgical facial rejuvenation, although efficacious, are uncomfortable for the patient. Preclinical studies have demonstrated that laser pretreatment at low energies enhances absorption of topical lidocaine. Objectives: The authors assess the safety and efficacy of laser-assisted transdermal delivery of topical anesthetic. Method: Ten patients were split into 2 groups (A and B). All patients received 15 g of BLT (20{\%} benzocaine, 6{\%} lidocaine, and 4{\%} tetracaine triple anesthetic cream) for 20 minutes with no occlusion. Then the cream was removed and the first blood draw taken. Group A patients were pretreated with the full ablative laser and group B patients with a fractional ablative laser to the full face. A further 15 g BLT was applied for another 20 minutes. Group A patients then underwent full ablative laser treatment, and group B received fractionated ablative laser treatment. Blood draws were taken at 60, 90, 120, 180, and 240 minutes after the initial topical anesthetic application, and the serum was analyzed for lidocaine and monoethylglycinexylidide (MEGX) levels. Patients were asked to rate the pain felt at intervals during the procedure. Results: No patient required supplemental nerve blocks. Pain scores were equivalent at the end of the first pass for both groups (P = .436). Group A patients had significantly lower pain scores at the start of the second laser treatment (P = .045), but pain scores became equivalent by the end (P = .323). Combined serum lidocaine and MEGX levels were significantly higher in group A patients up to 90 minutes (peak average of 0.61 μg/mL for group A and 0.533 {\`i}g/mL for group B; P = .0253), which corresponded to greater initial analgesic effect. Conclusions: Data from this study demonstrate that topical anesthetic for facial rejuvenation can be enhanced with laser pretreatment while maintaining safe blood serum levels. Further studies should examine optimal application amount and time to allow safe multipass facial rejuvenation without the need for invasive nerve blocks.",
keywords = "cosmetic medicine, laser-assisted transdermal delivery, pain, research, topical anesthetics",
author = "Georgette Oni and Yvonne Rasko and Jeffrey Kenkel",
year = "2013",
month = "8",
doi = "10.1177/1090820X13496248",
language = "English (US)",
volume = "33",
pages = "854--861",
journal = "Aesthetic Surgery Journal",
issn = "1090-820X",
publisher = "SAGE Publications Inc.",
number = "6",

}

TY - JOUR

T1 - Topical lidocaine enhanced by laser pretreatment

T2 - A safe and effective method of analgesia for facial rejuvenation

AU - Oni, Georgette

AU - Rasko, Yvonne

AU - Kenkel, Jeffrey

PY - 2013/8

Y1 - 2013/8

N2 - Background: Injectable forms of anesthesia for nonsurgical facial rejuvenation, although efficacious, are uncomfortable for the patient. Preclinical studies have demonstrated that laser pretreatment at low energies enhances absorption of topical lidocaine. Objectives: The authors assess the safety and efficacy of laser-assisted transdermal delivery of topical anesthetic. Method: Ten patients were split into 2 groups (A and B). All patients received 15 g of BLT (20% benzocaine, 6% lidocaine, and 4% tetracaine triple anesthetic cream) for 20 minutes with no occlusion. Then the cream was removed and the first blood draw taken. Group A patients were pretreated with the full ablative laser and group B patients with a fractional ablative laser to the full face. A further 15 g BLT was applied for another 20 minutes. Group A patients then underwent full ablative laser treatment, and group B received fractionated ablative laser treatment. Blood draws were taken at 60, 90, 120, 180, and 240 minutes after the initial topical anesthetic application, and the serum was analyzed for lidocaine and monoethylglycinexylidide (MEGX) levels. Patients were asked to rate the pain felt at intervals during the procedure. Results: No patient required supplemental nerve blocks. Pain scores were equivalent at the end of the first pass for both groups (P = .436). Group A patients had significantly lower pain scores at the start of the second laser treatment (P = .045), but pain scores became equivalent by the end (P = .323). Combined serum lidocaine and MEGX levels were significantly higher in group A patients up to 90 minutes (peak average of 0.61 μg/mL for group A and 0.533 ìg/mL for group B; P = .0253), which corresponded to greater initial analgesic effect. Conclusions: Data from this study demonstrate that topical anesthetic for facial rejuvenation can be enhanced with laser pretreatment while maintaining safe blood serum levels. Further studies should examine optimal application amount and time to allow safe multipass facial rejuvenation without the need for invasive nerve blocks.

AB - Background: Injectable forms of anesthesia for nonsurgical facial rejuvenation, although efficacious, are uncomfortable for the patient. Preclinical studies have demonstrated that laser pretreatment at low energies enhances absorption of topical lidocaine. Objectives: The authors assess the safety and efficacy of laser-assisted transdermal delivery of topical anesthetic. Method: Ten patients were split into 2 groups (A and B). All patients received 15 g of BLT (20% benzocaine, 6% lidocaine, and 4% tetracaine triple anesthetic cream) for 20 minutes with no occlusion. Then the cream was removed and the first blood draw taken. Group A patients were pretreated with the full ablative laser and group B patients with a fractional ablative laser to the full face. A further 15 g BLT was applied for another 20 minutes. Group A patients then underwent full ablative laser treatment, and group B received fractionated ablative laser treatment. Blood draws were taken at 60, 90, 120, 180, and 240 minutes after the initial topical anesthetic application, and the serum was analyzed for lidocaine and monoethylglycinexylidide (MEGX) levels. Patients were asked to rate the pain felt at intervals during the procedure. Results: No patient required supplemental nerve blocks. Pain scores were equivalent at the end of the first pass for both groups (P = .436). Group A patients had significantly lower pain scores at the start of the second laser treatment (P = .045), but pain scores became equivalent by the end (P = .323). Combined serum lidocaine and MEGX levels were significantly higher in group A patients up to 90 minutes (peak average of 0.61 μg/mL for group A and 0.533 ìg/mL for group B; P = .0253), which corresponded to greater initial analgesic effect. Conclusions: Data from this study demonstrate that topical anesthetic for facial rejuvenation can be enhanced with laser pretreatment while maintaining safe blood serum levels. Further studies should examine optimal application amount and time to allow safe multipass facial rejuvenation without the need for invasive nerve blocks.

KW - cosmetic medicine

KW - laser-assisted transdermal delivery

KW - pain

KW - research

KW - topical anesthetics

UR - http://www.scopus.com/inward/record.url?scp=84881161969&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84881161969&partnerID=8YFLogxK

U2 - 10.1177/1090820X13496248

DO - 10.1177/1090820X13496248

M3 - Article

C2 - 23908302

AN - SCOPUS:84881161969

VL - 33

SP - 854

EP - 861

JO - Aesthetic Surgery Journal

JF - Aesthetic Surgery Journal

SN - 1090-820X

IS - 6

ER -